Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 AI patient education for thyroid and chronic conditions at $125M valuation Sep 2024; $22.2M from Google, Harvard endowment, Gaingels/YC competing with Paloma Health for AI-driven medical knowledge accessibility for underdiagnosed chronic disease.
Rejoy Health is a San Francisco-based AI-powered healthcare platform — backed by Y Combinator (W21) with $22.2 million in total funding from Y Combinator, Google, Gaingels, and the Harvard University endowment fund, achieving a $125 million valuation in September 2024 — providing patients with chronic conditions (particularly thyroid disorders) with AI-driven medical knowledge accessibility tools and subscription-based treatment and management services that bridge the gap between patient symptoms, lab results, and clinical recommendations. Founded in 2020 by former Facebook and Microsoft engineers and launched through Y Combinator, Rejoy translates complex medical information into personalized, understandable patient guidance using artificial intelligence.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.